• Quarterly sales of $5.4 million, up 20% over previous quarter and 15% over prior year
• Revenue growth across all regions, with new US contract signed
• Continued development of automated, high-throughput solutions
• Strengthened leadership team with new CTO appointment

Genetic Signatures Ltd reported strong Q1 FY2026 results, with quarterly sales of $5.4 million, representing a 20% increase over the previous quarter and a 15% uplift compared to the prior corresponding period. The company saw revenue contribution from all three regions - Australia, EMEA and the US - with Australia gaining new business from existing customers, EMEA experiencing a 52% increase in Gastrointestinal (GI) testing, and the US receiving its first commercial order. The company signed a second US contract with an integrated healthcare organization, marking a key milestone in its US commercial expansion, with the first shipment of test kits delivered in September and testing expected to commence early in Q2 FY2026. The company also signed a third US contract with a previous customer experience site after the close of the quarter. The revised focused sales and marketing strategy, combined with improved brand awareness in key geographies, is providing a strong and growing pipeline of commercial opportunities. The company continued to develop its automated, high-throughput solution through the customizing of commercially available instruments, and strengthened its leadership team with the appointment of Dr. Susanne Pedersen as Chief Technology Officer. The company ended the quarter with a strong balance sheet, holding $28.2 million in cash and term deposits.

The company reported quarterly sales of $5.4 million, representing a 20% increase over the previous quarter and a 15% uplift compared to the prior corresponding period.

The company remains focused on strengthening its presence in Australia while accelerating global expansion, with particular emphasis on the United States and the United Kingdom. The company's solid cash position enables continued, targeted investment in commercial initiatives, while also supporting innovation across assay development, workflow optimisation, instrumentation, and software enhancements.